Fig. 3: Antitumor efficacy. | Nature Medicine

Fig. 3: Antitumor efficacy.

From: Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

Fig. 3: Antitumor efficacy.The alternative text for this image may have been generated using AI.

a,b, Tumor response: the best percentage change from baseline by treatment (investigator assessment) (a) and percentage change from baseline over time by treatment (investigator assessment) (b) in patients with sqNSCLC. PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page